Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541200 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
A Phase 2 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT03541200: Completed Phase 2 study, sponsored by Tanabe Pharma America.
NCT03541200 is a Phase 2 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 190 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03541200, a Phase 2 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01
Interventions
- DRUG MT-8554
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2019-11-15 |
| Phase | Phase 2 |
What the finished NCT03541200 record still lists
NCT03541200 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 1 intervention - of which MT-8554 is the first listed.
NCT03541200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03541200 about?
NCT03541200 is a clinical study titled "Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms". An open-label, long term extension study of MT-8554 in postmenopausal women experiencing moderate to severe vasomotor symptoms who completed Study MT-8554-A01
What is the current status of trial NCT03541200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2018-04-18. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT03541200?
The interventions under investigation include: MT-8554 (DRUG).
Who is sponsoring clinical trial NCT03541200?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03541200's enrollment target sits among peer trials
190 353rd of 2000 higher than 1,646 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI